Insider Selling: Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Insider Sells 4,000 Shares of Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) insider Thomas Gad sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $21.77, for a total transaction of $87,080.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Thomas Gad also recently made the following trade(s):

  • On Monday, July 8th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $22.40, for a total transaction of $89,600.00.
  • On Monday, June 10th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $22.79, for a total transaction of $91,160.00.
  • On Monday, June 3rd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.03, for a total transaction of $80,120.00.
  • On Tuesday, May 28th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $20.21, for a total transaction of $121,260.00.
  • On Monday, May 13th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $20.61, for a total transaction of $123,660.00.
  • On Thursday, April 11th, Thomas Gad sold 250,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $25.89, for a total transaction of $6,472,500.00.

YMAB traded up $0.25 during trading on Thursday, hitting $22.97. 76,176 shares of the company traded hands, compared to its average volume of 112,548. Y-mAbs Therapeutics, Inc has a one year low of $15.17 and a one year high of $31.00. The firm has a market capitalization of $786.80 million and a price-to-earnings ratio of -15.31. The company has a current ratio of 13.30, a quick ratio of 13.30 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average price is $22.03.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Friday, May 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.07). On average, research analysts anticipate that Y-mAbs Therapeutics, Inc will post -1.95 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on YMAB shares. Cowen reiterated a “buy” rating on shares of Ovid Therapeutics in a research report on Monday, July 1st. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Protalix Biotherapeutics in a research note on Monday, June 10th. Finally, Zacks Investment Research upgraded shares of ZovioInc . from a “sell” rating to a “hold” rating in a research note on Sunday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $30.80.

Several hedge funds have recently bought and sold shares of YMAB. BNP Paribas Arbitrage SA bought a new position in Y-mAbs Therapeutics during the first quarter valued at approximately $38,000. Citigroup Inc. purchased a new stake in Y-mAbs Therapeutics in the fourth quarter worth $37,000. American International Group Inc. purchased a new stake in Y-mAbs Therapeutics in the fourth quarter worth $93,000. Bank of America Corp DE lifted its stake in Y-mAbs Therapeutics by 3,056.5% in the fourth quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after acquiring an additional 5,838 shares during the period. Finally, Deutsche Bank AG purchased a new stake in Y-mAbs Therapeutics in the fourth quarter worth $191,000. Institutional investors own 24.80% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: How Do Investors Open a Backdoor Roth IRA?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.